PHAXIAM

PRESS RELEASE

PHAXIAM Therapeutics announces updated real-life clinical data from patients treated under the compassionate status in Europe

- **Promising clinical results observed in the first 88 patients evaluated so far, confirming the safety and an important clinical benefit for patients**
- **Control of the infection at 3 months for 79% of 52 evaluated patients having Prosthetic Joint Infections (PJI), either due to *Staphylococcus aureus* or *Pseudomonas aeruginosa***
- **Very consistent clinical data with recently disclosed PhagoDAIR clinical results, reaching a consolidated infection control rate at 3 months of 80% for 20 patients with PJI due to Staphylococcus *aureus***
- **Seven indications treated, with a majority of PJI cases and several routes of administration tested**

Lyon (France), January 7, 2025 – 06:00 pm CET - PHAXIAM Therapeutics (Euronext: PHXM - FR0011471135), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, today announces an update on its clinical data from patients treated with the Company's phages under the compassionate status.

Since 2017, PHAXIAM has treated more than 120 patients under Compassionate status, mostly suffering from hip or knee Prosthetic Joint Infections (PJI). The vast majority was treated in France but more and more compassionate patients are receiving PHAXIAM's phage therapy in other European countries.

Data from the first 88 patients evaluated so far show promising results, consistent with previous evaluation, i.e. an infection control at 3 months (clinical endpoint) reaching 75%. The latter is considered as a high rate and represents a significant improvement over the standard of care (SoC) in this "hard-to-treat" patient population with severe relapsing infection, often associated with antimicrobial resistance.

Among the patients evaluated, 52 suffered from PJI, either due to *Staphylococcus aureus* (*S. aureus PJI*, n=40) or *Pseudomonas aeruginosa* (*P. aeruginosa* PJI; n=12), with an overall control rate of 79% at 3 months observed in this population. 77% control rate was achieved in the *S. aureus* PJI sub-group and 83% control rate in the *P. aeruginosa* PJI sub-group. At 12 months, the data are not comprehensive so far, but the infection control rate is situated between 64% and 67%, which remains very high for this "hard-to-treat" population of patients with severe infections.

These clinical data are very consistent with those, recently presented, and stemming from the PhagoDAIR pilot study, according to which the consolidated infection control rate was 80% (16/20), including patients for whom phages were administered during DAIR or after a subsequent relapse leading to a rescue medication, with 1 or 3 administrations.

All these encouraging results confirm the relevance of launching the GLORIA Phase II POC trial.

In addition to PJI, several other clinical indications were targeted, such as osteomyelitis, vascular infections (including endocarditis, cardiac implants and bacteremia) and lung infections (including cystic fibrosis and ventilation-acquired pneumonia). Different administration routes, including local, intravenous and nebulisation were tested as well and were well tolerated.

More than half of the patients who were treated with PHAXIAM phages were treated within the "PHAGE*in*LYON *Clinic*" program that is supported by the "Fondation Hospices Civils de Lyon" set up at the Lyon University Hospitals (HCL – Hospices Civils de Lyon).

Within the framework of the compassionate treatments, several patients were treated under the AAC status (*Autorisation d'Accès Compassionnel* – compassionate access program) obtained by the Company in 2022 for its anti-*S. aureus* phages. Early 2025, PHAXIAM is planning to file for another AAC to treat patients with resistant *P. aeruginosa* infections. The objective is to expand as soon as possible the eligible population to PHAXIAM's phages under a compassionate status.

Pascal Birman, MD, Chief Medical Officer of PHAXIAM, stated: *"The data we share today are consistent with those obtained previously, and confirm the relevance of our clinical strategy focused on high-value indications, such as PJI, for which patients can take advantage of real clinical benefits. I would like to take this opportunity to thank the HCL clinical team led by Pr. Ferry, who performed more than half of the real-life compassionate treatments. Leveraging on these robust results, together with the clinical data from "PhagoDAIR" pilot study, we are more than ever focused on the acceleration of our PJI clinical development, through our lead global Phase II study (GLORIA).*

Pr. Tristan Ferry, Coordinator of the Referral Center for the Management of Complex Bone and Joint Infection (CRIOAC) at *Hôpital de la Croix-Rousse* (HCL, Lyon), added: *"These results show once again that phage therapy is particularly relevant when it comes to complex infections resistant to conventional treatments, such as PJI. We are glad to receive the ability from the French health ministry to centralize the requests at the national level, and to be able to select during multidisciplinary meetings which patients are the best candidate. We are treating a growing number of patients under the compassionate status and look forward to providing further clinical evidence to make phage therapy clearly recognized as a reference treatment."*

About CRIOAC Lyon

The *Centre de Référence des Infections Ostéo-articulaires Complexes* (CRIOAC - Reference Center for Complex Osteoarticular Infections) provides the multi-disciplinary care required to offer appropriate medical and surgical treatment, with a high level of expertise and competence.

For more information, please visit https://www.crioac-lyon.fr/en

About PHAXIAM Therapeutics

PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which are responsible for many serious infections. The company is building on an innovative approach based on the use of phages, natural bacterial-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections: *Staphylococcus aureus*, *Escherichia coli* and *Pseudomonas aeruginosa*.

PHAXIAM is listed on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

For more information, please visit www.phaxiam.com

Contacts

PHAXIAM
Thibaut du Fayet
CEO
+33 4 78 74 44 38
investors@phaxiam.com

NewCap
Mathilde Bohin / Dušan Orešanský
Investor Relations
Arthur Rouillé
Media Relations
+33 1 44 71 94 94
phaxiam@newcap.eu

Forward-looking information

This press release contains forward-looking statements, forecasts and estimates with respect to the clinical programs, development plans, business and regulatory strategy and anticipated future performance of PHAXIAM and of the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. All statements contained in this press release other than statements of historical facts are forward-looking statements. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond PHAXIAM's control. Therefore, actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Investor should carefully read the risk factors section of the Company which can be found in the Company’s regulatory filings with the French Autorité des Marchés Financiers (AMF), including in the Company’s 2023 Universal Registration Document (Document d’Enregistrement Universel) filed with the AMF on April 5, 2024 and future filings and reports by the Company. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. PHAXIAM disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in PHAXIAM’s expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by law.